Detection of 18F-FDG PET/CT Occult Lesions With 18F-DCFPyL PET/CT in a Patient With Metastatic Renal Cell Carcinoma. (January 2016)

• Record Type: Journal Article
• Authors: Rowe, Steven P.; Gorin, Michael A.; Hammers, Hans J.; Pomper, Martin G.; Allaf, Mohammad E.; Javadi, Mehrbod Som
• Is Part Of: Clinical nuclear medicine. Volume 41:Number 1(2016)
• Publication Date: 2016-01
• Subjects: metastatic renal cell carcinoma -- prostate-specific membrane antigen (PSMA) -- PET/CT; Nuclear medicine -- Periodicals; Radioisotope scanning -- Periodicals; Nuclear Medicine -- Periodicals; 616.07575
• DOI: 10.1097/RLU.0000000000000995
• Languages: English
• ISSNs: 0363-9762

Abstract

Abstract : Abstract: Renal cell carcinoma (RCC) is common with more than 60, 000 new cases in the United States yearly. No curative therapies are available for metastatic RCC. Improved methods of imaging metastatic RCC would be of value in identifying sites of occult disease and potentially for judging response to therapy. A 58-year-old man with known metastatic clear cell RCC was imaged with both 18 F-FDG and 18 F-DCFPyL PET/CT. 18 F-DCFPyL is a small molecule inhibitor of the prostate-specific membrane antigen (PSMA), a target known to be highly expressed on solid tumor neovasculature. Relative to 18 F-FDG, 18 F-DCFPyL identified more lesions and demonstrated higher tumor radiotracer uptake.